Progress in Cardiovascular Diseases
Volume 46, Issue 1 , Pages 79-90, July 2003

Oxidative stress and smoking-induced vascular injury

  • Anne Burke

      Affiliations

    • Gastrointestinal Division Philadelphia, PA, USA
  • ,
  • Garret A FitzGerald

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Garret A. FitzGerald, MD, Robinette Professor of Cardiovascular Medicine, Chairman, Department of Pharmacology, 153 Johnson Pavilion, University of Pennsylvania, 3620 Hamilton Walk, Philadelphia, PA 19104-6084, USA
    • Center for Experimental Therapeutics, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

Abstract 

The relative importance of mechanisms relevant to smoking-induced vascular injury is poorly understood. Cigarette smoke is a source of free radicals but also results in cellular activation and consequent generation of free radicals in vivo. Here we consider several approaches to estimating the consequences of free radical generation in vivo, using measurements of modified lipids, proteins, and DNA. Smoking appears to result in elevation of several biomarkers of oxidant stress, some in a dose-related fashion. There is also some evidence that disordered endothelial function in smokers may be partly attributable to oxidant stress. Other effects of smoking on hemostatic activation, sympathoadrenal function, and lipoprotein structure and function may also be modulated by smoking-induced oxidant stress. The emergence and application of rational quantitatively reliable indexes of oxidant stress in vivo is likely to elucidate the relative contribution of oxidant stress to smoking-induced vascular injury.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by grants (HL70128, HL-54500, HL-62250, HL61364, HL54500, and RR16293) from the National Institutes of Health. G.A.F. is the Robinette Foundation Professor of Cardiovascular Medicine and the Bobst Professor of Pharmacology.

PII: S0033-0620(03)00076-8

doi:10.1016/S0033-0620(03)00076-8

Progress in Cardiovascular Diseases
Volume 46, Issue 1 , Pages 79-90, July 2003